DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 33
- Registration Number
- NCT02448628
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
- Conditions
- Interventions
- First Posted Date
- 2015-02-25
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 120
- Registration Number
- NCT02371369
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 15
- Registration Number
- NCT02350712
- Locations
- 🇬🇧
University College London Hospital, London, United Kingdom
🇬🇧The Royal Marsden Hospital, London, United Kingdom
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2018-12-21
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 365
- Registration Number
- NCT02345057
A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 426
- Registration Number
- NCT02345044
Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 74
- Registration Number
- NCT02319369
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 66
- Registration Number
- NCT02303431
- Locations
- 🇫🇷
Hopital Arnaud de Villeneuve, Montpellier, France
🇨🇦McMaster Children's Hospital, Hamilton, Ontario, Canada
🇮🇳Institute of Child Health, Kolkata, India
Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 31
- Registration Number
- NCT02299661
- Locations
- 🇨🇿
: Hemodialysis Center, Teaching Hospital Hradec Králove, Hradec Kralove, Czechia
🇭🇺PRA Clinical Pharmacology Unit, Budapest, Hungary
Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 18
- Registration Number
- NCT02266940
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom
Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a
- First Posted Date
- 2014-10-10
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 48
- Registration Number
- NCT02261376
- Locations
- 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom